Quantcast

Meningococcal Vaccines Market Expected to Reach USD 3.76 Billion Globally in 2019: Transparency Market Research

May 9, 2014

ALBANY, New York, May 9, 2014 /PRNewswire/ –

According to a new report published by Transparency Market Research “Meningococcal
Vaccines Market (Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline
Analysis) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 -
2019,” the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is
expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013
to 2019.

Browse Meningococcal Vaccines Market Report With Full TOC

http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Meningococcal disease is caused by the bacterium Neisseria meningitidis and occurs
sporadically throughout the world with seasonal variations. It accounts for a proportion
of endemic bacterial meningitis, which can progress very rapidly leading to death within
24 hours from the onset of symptoms. The disease is often misinterpreted as common flu in
most of the cases. Five out of the several serogroups are known to cause meningococcal
disease. These serogroups responsible for the disease comprises serogroups A, B, C, Y and
W-135. The causative agent N. meningitidis is commonly found in the nasopharynx of humans
and gets transmitted through droplet inhalation by means of close contact such as exposure
to smokers, crowded living conditions such as dormitories, certain inherited disorders of
the immune system, functional/anatomical asplenia or though intimate oral contact among
others. According to European Federation of Pharmaceutical Industries and Association
every year meningitis affects almost 5 lakh people globally, primarily affecting toddlers,
infants and young adults, due to weaker immune system.

The global market for meningococcal vaccines is segmented broadly into vaccine types
namely, polysaccharide, conjugate and combination vaccines. The report also provides
analysis for vaccines under development that are expected to be commercialized during the
forecast period 2013 to 2019. The vaccine types are further segmented by different brands
available in the market. The conjugate vaccines segment is likely to lead the overall
meningococcal vaccines market in terms of revenue, which is estimated to reach
approximately USD 2.5 billion by 2019 at a CAGR of 12.9%. Amongst the pipeline vaccines,
Novartis’s Bexsero is expected to grow at the fastest rate of 24.7% during the forecast
period 2013 to 2019. According to Department of Health, U.K., Bexsero is the first
serogroup B vaccine to be incorporated into the national immunization program and is
expected to be available in the market for sales by the second quarter of 2014. The MnB
rLP2086 vaccine from Pfizer is currently in phase III clinical trials and has been granted
with Breakthrough Therapy status by U.S. FDA in 2014.

Geographically, North America lead the global meningococcal vaccines market in 2012
due to government interventions, wider immunization programs, and favorable research and
development initiative by manufacturers. According to National Meningitis Association of
the U.S., about 20 percent of all meningococcal disease cases occur in teens and young
adults aged 14 years to 24 years. As per the Centers for Disease Control and Prevention
(CDC) 1,000 to 2,600 people contract meningitis annually in the U.S. Meningococcal
vaccines licensed in the U.S. are only against A, C, Y and W-135 serogroups and not
against serogroup B. The use of Bexsero as an Investigational New Drug (IND) in combating
the disease during the outbreaks in Princeton University and University of California,
Santa Barbara in 2013, is likely to clear the way for Bexsero’s approval in the U.S.
market sooner than expected. This region is followed by Rest of the World comprising the
Latin American countries, the Middle East and African countries. This has been attributed
to the high incidence rate of meningococcal diseases in this region. Europe accounts for
the lowest CAGR due to rise free sales of the vaccines especially meningococcal C
vaccines.

By 2019, Asia-Pacific is estimated to be the fastest growing regional market with a
CAGR of around 17.1%. Major drivers for this market include low cost of manufacturing and
transfer of novel technologies with respect to vaccine manufacturing, from developed parts
of the world to the emerging economies. Advancements in manufacturing technology have been
helping companies in manufacturing novel products that are not only affordable in
developing and underprivileged nations, but are also comparable in terms of quality to
their high-end alternatives.

The global market for meningococcal vaccines is largely driven by increasing
government intervention in reforming the healthcare infrastructure and incorporation of
legislations specific to meningococcal vaccination. The public-private partnerships for
conducting research and development, and manufacturing of quality vaccines at an
affordable price are also contributing positively in driving market growth. Awareness
campaigning from government and non-profit organizations and obligatory immunization for
individuals heading to Mecca (for Hajj pilgrimage) and the South African meningitis belt
will also contribute to growth of this market. High cost of few but vital vaccines, such
as Bexsero, and need for efficient cold chain logistics to maintain safety and efficacy of
the vaccine are expected to be some of the major factors posing a challenge to the
adequate uptake of these vaccines.

The key players dominating in the global meningococcal vaccines include Sanofi Pasteur
(the vaccine division of Sanofi SA), Novartis International AG and GSK plc. These players
account for more than 80% of the meningococcal vaccines market. Players such as Serum
Institute of India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd., Nuron
Biotech and Baxter account for the remaining market share.

Related & Recently Published Reports by Transparency Market Research:

        - Ophthalmic Drugs Market:

http://www.transparencymarketresearch.com/ophthalmic-drugs-market.html

        - Clinical Laboratory Services Market:

http://www.transparencymarketresearch.com/clinical-laboratory-services-market.html

        - Blood Pressure Monitoring Testing Market:

http://www.transparencymarketresearch.com/blood-pressure-monitoring-market.html

        - Cell Surface Markers Market:

http://www.transparencymarketresearch.com/cell-surface-markers-market.html

        - Elderly and Disabled Assistive Devices Market:

http://www.transparencymarketresearch.com/elderly-disabled-assistive-devices.html

The global meningococcal vaccines market is segmented as follow:

Meningococcal Vaccines Market, by Type

        - Polysaccharide Vaccines, by Brand
             - Menomune
             - Mencevax
             - NmVac4
             - Others
        - Quadri Meningo
        - Bi Meningo
        - Conjugate Vaccines, by Brand
             - Menactra
             - Menveo
             - NeisVac-C
             - Nimenrix
             - Meningitec
             - Menjugate
             - MenAfriVac
        - Combination Vaccines, by Brand
             - MenHibrix
             - Menitorix
        - Pipeline Vaccines, by Brand
             - Bexsero
             - MnB rLP2806
             - NmVac4-DT

Browse Meningococcal Vaccines Market Report With Full TOC

http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Meningococcal Vaccines Market, by Geography

        - North America
        - Europe
        - Asia-Pacific
        - Rest of the World

Browse Pharmaceutical Market Reports @

http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of quantitative forecasting
and trends analysis provides forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts,
so that it always reflects the latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research material for business
reports.

Contact

Ms. Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Browse All Market Research Reports:

http://www.transparencymarketresearch.com/categories.html

Browse Market Research Articles:

http://www.transparencymarketresearch.com/articles.htm

Browse Market Research News:

http://www.transparencymarketresearch.com/press-releases.htm

Blog: http://www.tmrblog.com

SOURCE http://www.transparencymarketresearch.com/


Source: PR Newswire



comments powered by Disqus